Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients

G. Brandi, M. Nannini, M. A. Pantaleo, S. Fanello, M. Farsad, S. Fanti, G. Ercolani, A. Maleddu, M. Di Battista, G. Biasco

Research output: Contribution to journalArticle

Abstract

We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.

Original languageEnglish
Pages (from-to)421-424
Number of pages4
JournalChemotherapy
Volume54
Issue number6
DOIs
Publication statusPublished - Oct 2008

Keywords

  • Advanced colorectal cancer
  • Bevacizumab
  • PET

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Brandi, G., Nannini, M., Pantaleo, M. A., Fanello, S., Farsad, M., Fanti, S., Ercolani, G., Maleddu, A., Di Battista, M., & Biasco, G. (2008). Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy, 54(6), 421-424. https://doi.org/10.1159/000158540